Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

Bullboard Posts

Comment by alixx11on Sep 02, 2010 10:15am

347 Views

Post# 17407607

RE: RE: RE: RE: RE: Time for a breakout

LE,

While I also believe they had assays to report, my belief is that it was put on hold while they negotiated with ARZ (think about how long that probably took) and that since then all the focus has been on the start-up of the new drill program.

It just makes sense to me that whatever news they were planning to release before will be combined with the first drill results of this new program (again, my guesstimate is late fall for first results, given the drilling starts this month).

A.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario